✦ LIBER ✦

Safety, tolerability, and immunogenicity of a two-dose regimen of high-titer varicella vaccine in subjects ≥13 years of age

✍ Scribed by Clemente Diaz; Pietro Dentico; Rocio Gonzalez; Rafael G. Mendez; Sandro Cinquetti; Julie L. Barben; Anna Harmon; Ira Chalikonda; Jeffrey G. Smith; Jon E. Stek; Andrew Robertson; Michael J. Caulfield; Luigi R. Biasio; Jeffrey L. Silber; Christina Y. Chan; Rupert Vessey; Jerald Sadoff; Ivan S.F. Chan; Holly Matthews; William Wang; Katia Schlienger; Florian P. Schödel

Book ID: 116959122
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 592 KB
Volume: 24
Category: Article
ISSN: 0264-410X
DOI: 10.1016/j.vaccine.2006.06.030

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety, tolerability, and immunogenicity

Safety, tolerability, and immunogenicity of two regimens of Oka/Merck varicella vaccine (Varivax®) in healthy adolescents and adults

✍ Barbara J. Kuter; Angela Ngai; Carolyn M. Patterson; Brenda O. Staehle; Iksung C 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 795 KB

Immunogenicity and safety of a two-dose

Immunogenicity and safety of a two-dose regimen of a combined measles, mumps, rubella and varicella live vaccine (ProQuad®) in infants from 9 months of age

✍ Timo Vesikari; Thomas Becker; Vincent Gajdos; Anne Fiquet; Stéphane Thomas; Patr 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 918 KB

Safety and immunogenicity of a measles–m

Safety and immunogenicity of a measles–mumps–rubella–varicella vaccine given as a second dose in children up to six years of age

✍ Scott A. Halperin; Giuseppe Ferrera; David Scheifele; Gerald Predy; Giuseppe Ste 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 138 KB

Safety and tolerability of a high-potenc

Safety and tolerability of a high-potency zoster vaccine in adults ≥50 years of age

✍ Stephen K. Tyring; Francisco Diaz-Mitoma; Larry G. Padget; Margarita Nunez; Greg 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 407 KB

Safety, tolerability, and immunogenicity

Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age

✍ Joost N. Vermeulen; Joep M.A. Lange; Stephen K. Tyring; Patrick H. Peters; Marga 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 261 KB

Safety and Immunogenicity of Early Vacci

Safety and Immunogenicity of Early Vaccination with Two Doses of Tetravalent Measles-Mumps-Rubella-Varicella (MMRV) Vaccine in Healthy Children from 9 Months of Age

✍ P. Goh; F. S. Lim; H. H. Han; P. Willems 📂 Article 📅 2007 🏛 Springer-Verlag 🌐 English ⚖ 277 KB